Rigel Pharmaceuticals Inc. (RIGL) and partner AstraZeneca (AZN) reported clinical trial results for their oral treatment for rheumatoid arthritis, fostamatinib, which failed to meet one of the main objectives.
Rigel Pharmaceuticals gapped open sharply lower Thursday and fell further around mid-morning. Shares finished down by 2.92 at $5.51 on the highest volume of the year. The stock plummeted to a new low for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.